Apollo Hospitals Enterprise Limited — PPTs, 31-05-2025: Investor Presentation

1. Financial Highlights:

Apollo Hospitals’ consolidated revenue rose 14% to ₹21,794 Cr in FY25, led by all segments. Healthcare Services revenue grew 13% to ₹11,147 Cr with occupancy at 68% and ARPOB up 5%. EBITDA expanded 26% to ₹3,022 Cr (13.9% margin). Apollo HealthCo delivered 16% revenue growth to ₹9,093 Cr and turned profitable with a PAT of ₹47 Cr vs a loss last year, driven by cost optimization and scale. AHLL’s revenue increased 14% to ₹1,553 Cr with EBITDA up 32%. Consolidated PAT surged 61% to ₹1,446 Cr. Net debt was ₹2,830 Cr, supported by strong cash reserves.

2. Strategic Initiatives & Growth Drivers:

Apollo plans a ₹760 Cr capex in FY26 across major metros including Pune, Hyderabad, Delhi, Kolkata, and Mumbai, focusing on hospital expansion. Digital HealthCo is integrating Keimed (India’s largest pharma distributor with 70,000+ stores) to accelerate omni-channel pharmacy and private label growth (~₹1,500 Cr portfolio). Investments in AI-driven tools like Ask Apollo and ML-powered marketing are boosting engagement. AHLL is expanding dialysis, specialty clinics, and diagnostics with 110 new in-house tests added.

3. Business Developments:

Apollo achieved 25,000+ cumulative organ transplants and landmark surgeries, reinforcing complex care leadership. A knowledge-sharing MoU was signed with Indonesia’s Mayapada Healthcare. AHLL partnered with Eli Lilly for diabetes drug Mounjaro and launched the ProHealth Zen program in Bangalore. HealthCo enhanced app UX, launched insurance products with 12 partners, and expanded 19-minute medicine delivery to six cities.

4. Market Position & Competitive Advantage:

Apollo is India’s largest multi-specialty hospital chain with 73 hospitals and ~10,000 beds. Its omni-channel platform serves 40 Mn+ users and operates 6,626 retail outlets, backed by robust proprietary technology. Keimed’s integration bolsters supply chain scale and margin potential, building one of India’s leading integrated pharmacy and digital health platforms, targeting 7-8% EBITDA margins on ₹2,500 Cr+ revenue by FY27.

5. Investor Implications:

Strong revenue and margin growth alongside aggressive capex and digital investments highlight positive growth potential. The Keimed deal unlocks synergy and margin expansion in omni-channel healthcare. Execution risks around hospital expansion and digital integration warrant monitoring. Overall, fundamentals reflect improving profitability and healthy cash flow, supporting a constructive outlook for investors.